Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.

Wataru GotoShinichiro KashiwagiYuka AsanoKoji TakadaTamami MorisakiKatsuyuki TakahashiHisakazu FujitaMasatsune ShibutaniRyosuke AmanoTsutomu TakashimaShuhei TomitaKosei HirakawaMasaichi Ohira

Published in: BMC cancer (2020)

Although iron chelator induces oncogenic events (hypoxia, angiogenesis, EMT, and immune checkpoints), it may be an effective treatment for breast cancer when administered in combination with eribulin.

Keyphrases

metastatic breast cancer
endothelial cells
stem cells
epithelial mesenchymal transition
iron deficiency
transcription factor
vascular endothelial growth factor
randomized controlled trial
wound healing
replacement therapy
childhood cancer